Sign up
Pharma Capital

Collagen Solutions rises as it launches new online store

The online store will sell standard collagen products directly to end users in the research market
collagen
Collagen Solutions manufactures and supplies collagen for use in regenerative medicine and other medical research

Shares in Collagen Solutions PLC (LON:COS) edged higher on Monday morning after the medical grade collagen manufacturer launched a new business-to-consumer (B2C) web-based business in the US.

The online store will sell standard collagen products directly to end users in the research market.

The Minneapolis-headquartered group called the online offering an “important initiative” as it directly connects COS with its end users and allows it to better understand and address the purchasing needs of researchers.

The company told investors that, in the longer-term, that should help it to make sure it’s supplying the right products to the right markets, the company told investors.

“This initiative serves three purposes for Collagen Solutions,” said chief executive Jamal Rushdy.

“First, it increases our access to the estimated US$200m global market for cell culture reagents.

“Secondly, it gives us a direct link with the end users of our products so that we can understand their needs and how the market for collagen is evolving.

“Finally, it establishes Collagen Solutions as the go-to collagen supplier among investigators.”

Shares gained 5% to 5.14p on Monday morning.



Register here to be notified of future COS Company articles
View full COS profile

Collagen Solutions PLC Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.